Medical: Cardiology Press Releases
Who's Who in cardiovascular disease and prevention will present a range of issues -- from the controversial to the practical -- during a four-day meeting Feb. 6-9 of the 12th Annual Cardiovascular Disease Prevention International Symposium in sunny Miami Beach.
The CVRC status means that Hoag Hospital Irvine now is one of only 13 hospitals in Orange County, including Hoag Hospital Newport Beach, which can directly receive patients via ambulance who are suffering a heart attack and need immediate attention.
BTE Awards Certificate of Recognition for Commitment to Quality. ORLANDO, FLORIDA (March 23, 2012)-Orlando Heart Specialists has been awarded the Bridges to ExcellenceÂ® Cardiology Practice Recognition for meeting rigorous thresholds established by the American College of Cardiology and Bridges to ExcellenceÂ®.
A report released today by HealthGrades, the nation's most trusted, independent source of physician information and hospital quality ratings, recognized Englewood Hospital and Medical Center for its superior patient clinical outcomes by naming it among the top 10% in the nation for cardiac surgery and neurosciences as well as the top 5% for neurosurgery. Choosing a hospital can be a life or death decision.
Englewood Hospital and Medical Center's Cardiac Electrophysiology Laboratory lauds innovative technology that reduces the likelihood of heart failure sufferers being readmitted to the hospital for related additional procedures.
CareChex's release of America's Top Quality Hospitals includes Englewood Hospital and Medical Center for its outstanding medical care. "Englewood Hospital is a benchmark that other hospitals should seek to emulate."
J.D. Power and Associates' Distinguished Hospital Program SM acknowledges the exceptional patient experience established by Englewood Hospital and Medical Center in these fields.
The New York Cardiac Diagnostic Center accepts most insurance plans. By providing a cardiac consultation with a leading NYC cardiologist in the 10004 zip code, the Center can provide convenient heart disease prevention for those in the Wall Street area.
June 26, 2011. Surat, India. Sahajanand Medical Technologies (SMT) announced today that it has received European CE marking for two Sirolimus eluting coronary stent systems; SupralimusÂ® (Sirolimus eluting stents on stainless steel platform) & Supralimus-CoreÂ® (Sirolimus eluting stent on chromium cobalt platform).
Dr. Isaac Eliaz is unveiling surprising new ways to prevent the onset of cardiovascular disease.
The New York Cardiac Diagnostic Centers, now located through out the Manhattan area, has helped patients understand and determine if they are at risk for heart disease since 1987.
Chest Pain Accreditation: Fast, Coordinated, Expert Care
Website filled with information, on preventing heart attacks as well as preventing heart disease and even reversing it, now set in motion.
Medicomp, Inc. confirmed that it has received an initial ruling by the United States Patent and Trademark Office (USPTO) to reject all claims in regards to LifeWatch patent 7,542,878 (the '878 patent).
Medicomp introduces the new SAVI Wireless Mobile Cardiac Telemetry system. SAVI Wireless leverages Medicomp's proprietary Diogenes algorithm and the cellular network to provide real-time analysis and identification of cardiac arrhythmias.
Learn about the natural remedies for chronic bronchitis treatment.
"The 74th issue of prestigious international journal Catheterization and Cardiovascular Interventions published an article of Sahajanand Medical Technologies PAINT (PercutAneous INTervention) Trial - A randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (Paclitaxel or Sirolimus) compared against Bare stents: 1-year result."
Six Month Clinical Outcomes of SMT's Supralimus-Sirolimus Eluting Stent with a Biodegradable Polymer (part of the prospective Multicenter E-Series Registry) is presented at EuroPCR 2009.
International medical team announces one year patient results in adult stem cell clinical study for pulmonary hypertension.
"Sirolimus Eluting Stent for leading drug eluting Stents developer & manufacturer Sahajanand Medical Technologies Pvt. Ltd. (SMT) displayed positive results in MAXIMUS trial that included 100 patients from the Max Heart institute in India"